Bone Metastasis on the Survival of Gefitinib Effective Patients

Summary

Gefitinib is a selective small molecule epidermal growth factor receptors (EGFR) tyrosine kinase inhibitors (EGFR-TKI), it's curative effect on non-small cell lung cancer (NSCLC) has been confirmed by a number of prospective clinical trials. The researches aim to analysis whether bone metastasis could affect the survival of NSCLC patients who were effective in Gefitinib treatment over 6 months.

Timeline

Start

2009-05-01

Primary completion

2013-05-01

Completion

2015-07-12

Drugs

Indications